PDCD1 and cancer: Besides, most anti‐PD‐L1 antibodies can merely target the PD‐1/PD‐L1 axis on the surface of immune cells and cancer cells rather than intracellular PD‐L1 protein, meaning that these antibodies may not affect the reinforced DNA damage repair (DDR) process mediated by enhanced PD‐L1 expression after radiotherapy.[6, 8] To sum up, blocking the membranal and intracellular PD‐L1 simultaneously may better enhance the efficacy of radiotherapy in lung cancer therapy.